Patient P-02265

Synthetic patientMETA-24 · Day 171 · 45–54 · F · baseline S07Steering view · 3D Open companion preview

Therapy response

Favorable

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

69%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S07
Day 117 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 122 GI-04 recommended — GI Support Protocol GI-04
Day 123 Patient accepted — Started GI-04 in the companion
Day 131 No meaningful change — GI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 117.

Primary contributors, last 14 days

Inflammatory activity+17
GI instability+11
Nutritional resilience-11
Toxicity+7
Treatment adherence+4

What helped?

GI Support Protocol GI-04Day 122
Result: no meaningful change

LIFE OS recommendation

Monitoring Escalation ME-01

85%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

28 min

worsening · -7.9 vs previous 14 d

Sleep duration

Wearable

6.1 h

worsening · -0.4 vs previous 14 d

Energy level

Daily log

2.6/10

worsening · -0.8 vs previous 14 d

Steps

Wearable

3,975

worsening · -957 vs previous 14 d

GI burden

Companion

62/100

worsening · +12.1 vs previous 14 d

Adherence

Companion

68.4 %

worsening · -4.4 vs previous 14 d

Sleep quality

Wearable

25.5/100

worsening · -7.1 vs previous 14 d

Glucose, CGM daily mean

CGM

149 mg/dL

worsening · +9.4 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 44 from the failing basin, 60 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 42 similar · onset 3 d · confidence 73%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 73%
SC-12 Supportive Compound
69% improved among 26 similar · onset 6 d · confidence 73%
More protein
GI -5.5 next day on high-intake days · n 24

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
Keep histamine low
GI +5.4 next day on high-intake days · n 25
Keep caffeine low
GI +5.2 next day on high-intake days · n 26
Keep fat low
GI +4.2 next day on high-intake days · n 27

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-5.5supporter · 95%
Histamine load
+5.4detractor · 95%
Caffeine
+5.2detractor · 95%
Dietary fat load
+4.2detractor · 95%
Ultra-processed food
+4.2detractor · 95%
Simple carbohydrates
+1.1no signal · 25%
Insoluble fibre
+0.6no signal · 15%
Alcohol
+0.5no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 61
- WearableHRV 22 ms, trending down
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 83 bpm
- Wearable3,975 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 62 and rising
- WearableSleep 6.1 h, below personal baseline
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 49

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 3.1 · butyrate capacity 40/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 22 ms
Sleep: 6.1 h
Steps: 3,679
Resting HR: 81 bpm

Daily log: GI score 62, nutritional resilience 33, adherence 68.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02530	57%	S07	—	—	67
P-02334	51%	S04	GI-04	improved	66
P-02433	49%	S07	GI-04	improved	61
P-02136	46%	S10	—	—	63
P-02084	44%	S11	GI-04	no change	58
P-02029	43%	S18	—	—	56
P-02631	43%	S17	—	—	58
P-02591	42%	S13	—	—	68
P-02595	40%	S02	—	—	53
P-02046	39%	S10	—	—	55
P-02078	39%	S04	—	—	56
P-02054	38%	S01	CR-01	improved	57